• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    8/3/23 1:31:07 PM ET
    $ADMP
    $AHI
    $ARAV
    $BJDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $ADMP alert in real time by email

    Gainers

    • T2 Biosystems (NASDAQ:TTOO) stock increased by 63.0% to $0.4 during Thursday's regular session. The current volume of 381.1 million shares is 611.2% of T2 Biosystems's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $114.9 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) stock increased by 60.43% to $8.76. Bluejay Diagnostics's stock is trading at a volume of 9.8 million shares as of 13:30 EST. This is 2506.7% of its average full-day volume over the last 100 days. The company's market cap stands at $8.9 million.
    • Corcept Therapeutics (NASDAQ:CORT) stock rose 25.5% to $31.39. As of 13:30 EST, this security is trading at a volume of 3.1 million shares, making up 555.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.1 billion. As per the press release, Q2 earnings came out yesterday.
    • Adamis Pharmaceuticals (NASDAQ:ADMP) shares moved upwards by 25.46% to $1.67. The current volume of 52.7 million shares is 6196.9% of Adamis Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $4.6 million.
    • Advanced Health (NASDAQ:AHI) stock increased by 23.62% to $3.82. The company's market cap stands at $26.7 million.
    • Cyclo Therapeutics (NASDAQ:CYTH) stock rose 21.47% to $1.81. Cyclo Therapeutics's stock is trading at a volume of 193.0K shares as of 13:30 EST. This is 195.3% of its average full-day volume over the last 100 days. The company's market cap stands at $27.7 million.

    Losers

    • Aravive (NASDAQ:ARAV) stock fell 72.5% to $0.35 during Thursday's regular session. Trading volume for Aravive's stock is 31.4 million as of 13:30 EST. This is 8726.9% of its average full-day volume over the last 100 days. The company's market cap stands at $20.9 million.
    • Bio-Path Hldgs (NASDAQ:BPTH) stock fell 45.96% to $0.41. Trading volume for Bio-Path Hldgs's stock is 5.4 million as of 13:30 EST. This is 4171.1% of its average full-day volume over the last 100 days. The company's market cap stands at $3.2 million.
    • Vicarious Surgical (NYSE:RBOT) stock decreased by 42.53% to $0.95. As of 13:30 EST, Vicarious Surgical's stock is trading at a volume of 14.2 million, which is 5125.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $120.7 million.
    • Schrodinger (NASDAQ:SDGR) stock declined by 23.72% to $38.33. As of 13:30 EST, Schrodinger's stock is trading at a volume of 3.3 million, which is 227.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.7 billion. The company's, Q2 earnings came out yesterday.
    • INVO Bioscience (NASDAQ:INVO) stock declined by 21.34% to $3.12. As of 13:30 EST, INVO Bioscience's stock is trading at a volume of 187.7K, which is 92.6% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 million.
    • Trxade Health (NASDAQ:MEDS) shares decreased by 18.52% to $8.71. Trading volume for this security as of 13:30 EST is 232.1K, which is 36.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $AHI
    $ARAV
    $BJDX

    CompanyDatePrice TargetRatingAnalyst
    Corcept Therapeutics Incorporated
    $CORT
    12/31/2025$30.00Peer Perform → Underperform
    Wolfe Research
    Corcept Therapeutics Incorporated
    $CORT
    12/16/2025Neutral
    UBS
    Schrodinger Inc.
    $SDGR
    12/15/2025$24.00Neutral → Buy
    BofA Securities
    Corcept Therapeutics Incorporated
    $CORT
    11/18/2025Peer Perform
    Wolfe Research
    Schrodinger Inc.
    $SDGR
    9/30/2025$19.00Neutral
    Goldman
    Schrodinger Inc.
    $SDGR
    8/15/2025$20.00Buy → Neutral
    Citigroup
    Schrodinger Inc.
    $SDGR
    8/14/2025$25.00Overweight
    Barclays
    Schrodinger Inc.
    $SDGR
    7/3/2025$28.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ADMP
    $AHI
    $ARAV
    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CAO Herman Jenny sold $17,764 worth of shares (1,383 units at $12.84), decreasing direct ownership by 4% to 34,804 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/6/26 5:29:46 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Jain Rachit sold $21,033 worth of shares (1,631 units at $12.90), decreasing direct ownership by 3% to 52,596 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/6/26 5:29:05 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO & CPO Tran Yvonne sold $14,107 worth of shares (1,094 units at $12.89), decreasing direct ownership by 2% to 52,683 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/6/26 5:28:37 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHI
    $ARAV
    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

    ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests for critical care conditions, today announced that an abstract related to its Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting, which will take place May 18–21, 2026 in Atlanta, Georgia. The presentation will report findings from SYMON-I, a multicenter pilot clinical study evaluating interleukin-6 (IL-6) levels in patients with sepsis who were admitted or intended for admission to the intensive care unit (ICU). The analysis evalu

    3/12/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

    ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026. Operational and Clinical ProgressBluejay continues to advance its Symphony™ platform, including the Company's lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making. The Company confirmed that its SYMON™ II clinical study is progressing as planned, with on

    3/6/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Vicarious Surgical Receives Delisting Notice From NYSE

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

    3/4/26 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $ADMP
    $AHI
    $ARAV
    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Corcept Therapeutics downgraded by Wolfe Research with a new price target

    Wolfe Research downgraded Corcept Therapeutics from Peer Perform to Underperform and set a new price target of $30.00

    12/31/25 9:53:16 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Corcept Therapeutics

    UBS initiated coverage of Corcept Therapeutics with a rating of Neutral

    12/16/25 8:47:55 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger upgraded by BofA Securities with a new price target

    BofA Securities upgraded Schrodinger from Neutral to Buy and set a new price target of $24.00

    12/15/25 9:09:21 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHI
    $ARAV
    $BJDX
    SEC Filings

    View All

    SEC Form PRE 14A filed by Vicarious Surgical Inc.

    PRE 14A - Vicarious Surgical Inc. (0001812173) (Filer)

    3/13/26 4:51:44 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Schrodinger Inc. filed SEC Form 8-K: Leadership Update

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    3/12/26 4:10:49 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/12/26 12:24:37 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ADMP
    $AHI
    $ARAV
    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

    4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    12/14/23 4:17:42 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

    4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    12/14/23 4:16:33 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ADMP
    $AHI
    $ARAV
    $BJDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHI
    $ARAV
    $BJDX
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w

    5/29/25 8:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer

    Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h

    3/13/25 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $ADMP
    $AHI
    $ARAV
    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

    SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 3:54:54 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by T2 Biosystems Inc.

    SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

    11/14/24 3:38:45 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    $ADMP
    $AHI
    $ARAV
    $BJDX
    Financials

    Live finance-specific insights

    View All

    Vicarious Surgical Receives Delisting Notice From NYSE

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

    3/4/26 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

    2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028 Accelerating Transition to Ratable, Hosted Software Revenue Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives. "Schrödinger's performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "

    2/25/26 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

    2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr

    2/24/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care